{"id":6484,"date":"2020-06-25T23:53:46","date_gmt":"2020-06-25T21:53:46","guid":{"rendered":"http:\/\/mapsofthemind.com\/?p=6484"},"modified":"2023-03-02T15:39:03","modified_gmt":"2023-03-02T14:39:03","slug":"how-to-get-dose-right-psilocybin-magic-truffle-dosage","status":"publish","type":"post","link":"https:\/\/mapsofthemind.com\/2020\/06\/25\/how-to-get-dose-right-psilocybin-magic-truffle-dosage\/","title":{"rendered":"How to Get the Dose Right with Psilocybin Truffles"},"content":{"rendered":"
One of the most important factors leading to a beneficial magic truffle session is finding a dosage that is well calibrated to your intention. I would argue that it is of equal importance to the set and setting when it comes to a positive outcome.<\/p>\n
As magic truffles are kinda new in the psychedelic world compared to classic magic mushrooms, the doses are not well understood.<\/p>\n
Below, I\u2019ll share my calculations to match the doses of synthetic psilocybin used in 4 major and influential studies to the corresponding dose of magic truffles. Synthetic psilocybin is easy to measure and dose compared to raw mushrooms, and is therefore used exclusively in clinical trials. Below, I share my calculations.<\/p>\n
<\/p>\n
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors – Roland R. Griffiths, Matthew W. Johnson, William A. Richards, Brian D. Richards, Robert Jesse, Katherine A. MacLean, Frederick S. Barrett, Mary P. Cosimano, and Maggie A. Klinedinst (2018)<\/p>\n
Participants tripped twice, with a month between each session, with:
\n(1) high dose of 20 mg
\n(2) high dose of 30 mg
\nDoses calculated per 70kg bodyweight.<\/p>\n
Study paper<\/a><\/p>\n Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study – Robin L. Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M.J. Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding, David Taylor, Steve Pilling, Valerie H. Curran, David J. Nutt (2016)<\/p>\n Participants tripped twice, with a week between each session: Study paper<\/a><\/p>\n Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial – Roland R. Griffiths, Matthew W. Johnson, Michael A. Carducci, Annie Umbricht, William A. Richards, Brian D. Richards, Mary P. Cosimano and Margaret A. Klinedinst (2016)<\/p>\n Participants tripped twice, with 5 weeks between each session: Study paper<\/a><\/p>\n Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction – Matthew W. Johnson, Albert Garcia-Romeu, Mary P. Cosimano, and Roland R. Griffiths (2014)<\/p>\n On a 15 week course participants tripped 2-3 times: Study paper<\/a><\/p>\n2. Psilocybin with psychological support for treatment-resistant depression<\/h3>\n
\n(1) low dose of 10 mg
\n(2) high dose of 25 mg
\nDoses regardless of bodyweight.<\/p>\n3. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer<\/h3>\n
\n(1) high dose of 22 or 30 mg
\n(2) very low (placebo-like) dose of 1 or 3 mg
\nDoses calculated per 70kg bodyweight.<\/p>\n4. Psilocybin in the Treatment of Tobacco Addiction<\/h3>\n
\n(1) moderate dose of 20mg at week 5
\n(2) moderate or high dose of 20 or 30 mg at week 7
\n(3) optional session with either 20 or 30 mg at week 13
\nDoses calculated per 70kg bodyweight.<\/p>\nConverting to Fresh Truffle Weight<\/h2>\n